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In previous studies, Phorbol-12-myristate-13-acetate (PMA)-
treated human keratinocytes (PMA-HNK) were shown to 
induce T-cell proliferation via a major histocompatibility 
complex (MHC)- and antigen (Ag)-independent mecha-
nism, that was mediated in part by PMA-induced intercellu-
lar adhesion molecule (ICAM)-l on HNK. Recently, the 
interaction of the B7 Ag on antigen-presenting cells with its 
ligand CD28 on T cells has been shown to deliver activation 
signals distinct from the interaction of MHC/ Ag with the 
T-cell receptor. These findings led us to assess whether 
B7 -dependent signals playa role in T-cell proliferation in-
duced by PMA-HNK. We first examined B7 expression on 
HNK by staining with three different monoclonal antibodies 
(MoAbs). When analyzed by fluorescence-activated cell 
sorter, untreated HNK stained only faintly. By contrast, 
K eratinocytes (KC), the major cell type within epider-mis, have long been thought to contribute to T-ceIl-mediated immune responses in skin [1 - 3]. For exam-ple, KC secrete a variety of cytokines that modulate T-cell functions [3]. KC have also been shown to 
express major histocompatibility complex (MHC) class II antigen 
(A g) in inflammatory dermatoses characterized by infiltrating T 
cells [4], raising the possibility that these KC participate in T-cell 
activation; however, normal KC that express MHC class II Ag after 
in vitro stimulation with interferon-yare at best weak stimulators of 
T-cell proliferation [5 -9]. In fact, MHC class II-positive KC have 
been shown to induce tolerance in selected T cells [10,11]. 
In previous work, we demonstrated that phorbol-12-myristate-
13-acetate (PMA)-treated cultured human KC (PMA-HNK) can 
stimulate the proliferation of resting allogeneic or autologous T 
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PMA induced a dose-dependent upregulation ofB7 staining. 
This staining identifies a molecule closely related to B7 be-
cause it was blocked by purified recombinant B7 immuno-
globulin. U pregulation ofB7 staining was first observed 16 h 
after PMA treatment and persisted for at least 48 h; it was 
protein kinase C dependent and required de novo protein syn-
thesis . Anti-B7 MoAbs reduced specifically the capacity of 
PMA-HNK to trigger proliferation of allogeneic peripheral 
blood mononuclear cells and T cells. The combination of 
anti-B7 and anti-ICAM-1 MoAbs further reduced this re-
sponse. We conclude that PMA upregulates on HNK the 
expression of a B7-like molecule that contributes in concert 
with ICAM-1 to the capacity ofPMA-HNK to induce prolif-
eration of allogeneic T cells.] Invest D ermatol1 00:275 -281, 
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cells via an MHC-independent mechanism that is mediated in part 
by PMA-induced intercellular adhesion molecule (ICAM)-l on 
HNK [12]. These studies demonstrated for the first time that "acti-
vated" HNK can directly trigger a proliferative response in T cells. 
Interaction between ICAM-l (on PMA-HNK) and lymphocyte 
function-associated antigen (CDllajCD18) (LFA)-t (on T cells) 
was necessary ~ut not suffi.cient for this effect, raising the possibility 
that other costlmulatory Signals delivered by PMA-HNK were also 
required for efficient T-cell activation. 
Recent~y, t.he i.nteraction of the B7 Ag [on antigen-presenting cell 
(APC)] wIth Its hgand CD28 (on T cells) has been shown to deliver 
activation signals to T cells distinct from those transduced via the 
T-cell receptor [13-17]. B7 is also called BBt because it was ini-
tially identified by two different antibodies (i.e., B7 and BB 1) that 
recognize identical (or highly related) glycoproteins with a molecu-
ICAM-l: intercellular adhesion molecule 1 
Ig: immunoglobulin(s) 
KC: keratinocyte(s) 
KGM: keratinocyte growth medium 
LFA-l: lymphocyte function-associated antigen (CDlla/CD18) 
MHC: major histocompatibility complex 
MoAb: monoclonal antibody 
PBMC: peripheral blood mononuclear cell(s) 
PBS: phosphate-buffered saline 
PI: propidiurn iodide 
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lar weight of 44 - 54 kDa. B7 shows low constitutive expression on 
resting B cells and monocytes; however, it can be readily upregu-
lated by stimulation with mitogen, cytokines, anti-immunoglobu-
lins (Ig), or anti-class II antibodies or by Epstein - Barr virus-
transformation [18-22]. In addition, B7 is expressed on different 
B-celllines and B-cell neoplasms and on human T-celllymphotro-
pic virus-l-infected T-cell lines [18-20,23] . CD28 is a 44-kDa 
homodimeric glycoprotein expressed by the m~ority of T cells in 
human peripheral blood [15,24-26]. Interaction ofB7 and CD28 
has been shown to mediate heterotypic adhesion of T and B cells 
[27] and to augment several T-cell functions, such as proliferation, 
cytokine production, adhesion, and cytotoxicity [17,28 - 37]. De-
fective signalling via the B7/CD28 pathway has been implicated in 
the development of T-cell tolerance [38]. Taken together, these 
studies indicate that interaction ofB7 with CD28 delivers essential 
costimulatory signals, resulting in effective induction and amplifi-
cation of T -cell- mediated immune responses [13 -17]. 
In the present study, we questioned whether B7-associated sig-
nals may contribute to the capacity ofPMA-HNK to induce T-cell 
proliferation. Indeed, PMA-HNK upregulate the expression of a 
surface molecule closely related to B7 on B cells and monocytes. 
This molecule, is functionally active because it contributes to the 
capability of PMA-HNK to activate resting allogeneic peripheral 
blood mononuclear cells (PBMe) or T cells. Furthermore, this B7 
molecule and ICAM-l expressed simultaneously by PMA-HNK 
were found to cooperate in delivering activation signals to T cells. 
On the basis of these findings, we hypothesize that during T-cell-
mediated skin disease, B7 and ICAM-1 are co-expressed on "acti-
vated" epidermal and dermal cells and mediate adhesion and activa-
tion of T lymphocytes. 
MATERIALS AND METHODS 
Media and Chemicals Serum-free keratinocyte basal growth 
medium (KGM) was supplemented with recombinant epidermal 
growth factor, bovine pituitary extract, and 1 % penicillin -
streptomycin (all from Gibco, Eggenstein, Germany). RPMI 1640 
(Gibco) was supplemented with 10% heat-inactivated fetal bovine 
serum; 25 mM N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic 
acid (Sigma Chemical Co., Munich, Germany); 1 mM non-essen-
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tial amino acids (Gibco); 2 mM L-glutamine (Gibco); 1 nM 2-mer-
captoethanol (Sigma); and 1% penicillin -streptomycin (Gibco). 
Minimal essential medium (Gibco) was supplemented with 1.282 
Dornase U/ml DNAse I (Boehringer, Ingelheim, Germany), 10% 
fetal bovine serum, and 1 % penicillin-streptomycin (Gibco). PMA 
and 0.05% trypsin plus 0.02% ethylenediaminetetraacetic acid 
(EDTA) were purchased from Gibco. Radiolabeled [methyPH]-
thymidine (TdR) (5 Ci/mM) was obtained from Amersham, Inc. 
(Braunschweig, FRG) . The specific protein kinase C inhibitor GF 
109203X [39] was a generous gift of Dr. C. Schaechtele, Godecke 
AG, Freiburg, Germany. 
Monoclonal antibodies and Fusion Proteins The following 
monoclonal antibodies (MoAbs) directed against the B7 Ag were 
used: BBl (lgM) (mouse IgM [19]), 104 (mouse IgG, [22,23]; a 
generous gift of Dr. ]. Bancherau), and BBl (IgG) (mouse IgG,; 
Becton Dickinson, Heidelberg, Germany). The anti-ICAM-l 
MoAb 84HI0 (mouse IgG,) was purchased from Immunotech 
(Marseille, France). The recombinant fusion protein B7 -Ig was gen-
erated as previously described [40,41]. As isotype controls, MoAb 
HN2 (mouse IgM, anti-Mouse lab; a gift of Dr. Ledbetter) and 
X63Ag8 (mouse IgG,) or purified human IgG (both from Dianova, 
Hamburg, Germany) were used. 
HNK Culture Human foreskin discarded after circumcision was 
cut into 1 X l-cm pieces and floated in 0.5% dispase (neutral pro-
tease grade II; Boehringer Mannheim) for 180 min at 37°C to 
separate epidermis from dermis. Epidermal sheets were placed in 
0.3% trypsin (type XI; Sigma) in a buffer solution containing 0.17% 
glucose, 0.88% NaCI, and 0.04% KCl for 10 min at 37°C. Stratum 
corneum and other debris were removed by filtration through 
Sera-Sepra columns (Evergreen Scientific, Los Angeles, CA). Dis-
aggregated epidermal cells (Ee) were washed in modified Eagle's 
medium and resuspended in supplemented KGM. EC viability was 
estimated by trypan blue exclusion to range from 85% to 97%. EC 
were seeded into 75-cm2 tissue culture flasks (Greiner, Frickenhau-
sen, Germany) to establish primary keratinocyte cultures. On con-
fluency, cells were split using 0.05% trypsin plus 0.02% EDTA, 
washed twice in Hank's balanced salt solution resuspended in KGM, 
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Figure 1. PMA treatment upregulates B7 staining on HNK. Second-passage HNK suspended in KGM were left untreated (lOp row) or were treated with 
25 !-lg/ml PMA (bottom row). After 16 h at 37°C m 5% CC?2' HNK were .harvested and stained with MoAbs BB1 (IgM), 104 (IgG 1), BB1 (IgG 1) (solid curves) 
or ISO type controls (dotted curves), followed by appropnate FITC-conJugated secondary reagents. Staining was evaluated using a Becton Dickinson 
FACScan collecting 15,000 cells/sample. HNK viability was determined by PI staining and exceeded 90% in all experiments. Each graph displays FITC 
fluorescence of live (PI-negative) HNK. 
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During subsequent passages, HNK were harvested and reseeded 
identically. For the experiments outlined below, second- to fifth-
passage HNK from 21 different donors were used. 
Isolation of PBMC and T-Cell Purification PBMC were 
enriched from heparinized peripheral blood obtained from human 
volunteers by density centrifugation over 1.077 Histopaque 
(Sigma). Cells recovered from the interface were washed and resus-
pended in supplemented RPMI 1640. PBMC viability was greater 
than 90%, as determined by trypan blue exclusion. T cells were 
purified as previously described [42]. Briefly, PBMC were layered 
on glass petri dishes (1 h, 37 °C), and non-adherent cells were 
treated with L-Leucine-O-methyl ester (0.45,ug/ml, 1 h, room tem-
perature) to remove monocytes and finally passed over nylon wool 
columns (NEN Products, Boston, MA). The resulting CD3+ popu-
lations were more than 90% pure, as determined by f1uorescence-
activated cell sorter (FACS) analysis and did not proliferate in re-
sponse to 0.5 ,ug/ml concanavalin A. 
Immunostaining and FACS Analysis Sixteen hours prior to 
staining, HNK were treated with PMA at the indicated concentra-
tions or left untreated . HNK were harvested as described above, and 
viability, determined by trypan blue exclusion, ranged from 80% to 
90%. Prior to staining with MoAb, HNK were pre-incubated with 
0.1 % bovine serum albumin in phosphate-buffered saline (PBS) for 
30 min at 37"C in 5% CO2 to block non-specific antibody binding, 
washed twice, and then resuspended in PBS containing 0.1 % so-
dium azide. Cells were aliquoted at 3 - 6 X 105 into polystyrene 
tubes, and all staining was performed for 20 min at 4 ° C using the 
indicated primary reagents. HNK labeled with irrelevant MoAb of 
the same isotype served as specificity controls. In some experiments, 
anti-B7 MoAbs were pre-incubated with purified B7-Ig or human 
IgG (lh, 4 °C) prior to use. After two washes in PBS, HNK were 
counterstained with appropriate fluorescein isothiocyanate 
(FITC) -conjugated secondary antibodies [i.e., goat anti-mouse,u-
chain, F(ab')z fragments of goat anti-mouse IgG or goat anti-mouse 
IgG (heavy and light chain) (both from Dianova, Hamburg, Ger-
many)]. Cells were analyzed by flow cytometry using an FACScan 
(Becton Dickinson, Sunnyvale, CA) equipped with the Consort 30 
and FACScan research software. Propidium iodide (PI) (1 ,u/ml) 
was added to each sample to exclude dead cells. 
Proliferation Assays HNK (second to fifth passages) were sus-
pended in KGM and seeded into 96-well plates at 2 X 104 cells/ 
dish . After 3 - 4 d, HNK were treated with 0 or 25 ng/ml PMA for 
16 h at 37 °C in 5% CO2 • Initially, keratinocytes (KC) were y-irra-
diated (3000 rad, 137CS); however, because irradiated and unirra-
diated KC showed the same background proliferation and acted 
equally as stimulators of PBMC or T-cell proliferation, they were 
omitted after several experiments. After PMA treatment, HNK 
were washed five times to remove residual PMA, and allogeneic 
PBMC or T cells suspended in supplemented RPMI, including in-
domethacin (1 pg/ml), were added to the HNK at 5 X 104 cells/ 
dish. These were incubated for 72 h at 37°C in 5% CO2 • Cocul-
tures were pulsed for an additional 18 h with TdR (1 ,uCi/well) and 
then collected onto nitrocellulose filter paper using a Skatron cell 
harvester. Incorporated TdR was determined by liquid scintillation 
spectroscopy. All cultures were carried out in triplicate, and results 
were calculated as the mean cpm ± SD. In blocking experiments, 
MoAbs or appropriate isotype controls were added to the PBMC or 
T cells at· the indicated concentrations and remained in the cocul-
tures throughout the incubation period. 
RESULTS 
To determine whether HNK express the B7 Ag, cultured HNK 
(second to fifth passages) were stained with three different anti-B7 
antibodies and analyzed by FACS. Unstimulated HNK displayed 
only faint staining compared with the appropriate controls (Fig 1). 
It should be noted, however, that this low constitutive B7 staining 
varied among HNK lines established from different donors (data 
not shown). Following PMA treatment, B7 staining was markedly 
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Figure 2. Specific inhibition of PMA-induced B7 staining by purified 
B7-lg. The anti-B7 MoAb BBl was pre-incubated with a recombinant 
puri.fied B7-lg fusion protein (anti-B7 + B7-lg) or an irrelevant human 
IgG [anti-B7 + control (ctrl.)] for 1 h at 4°C and then used to stain HNK 
that had been PMA treated as described in Fig 1. PMA-HNK that had 
been stained only with anti-B7 MoAb (anti-B7) or an irrelevant IgM 
MoAb (ctrl.) served as positive or negative controls, respectively. Staining 
was analyzed using a Becton Dickinson FACScan, as described in Fig 1. 
upregulated (Fig 1). Again, the intensity of this PMA-induced 
staining varied among different HNK lines (data not shown). It 
should also be noted that in five of a total of 36 experiments, no 
upregulation of B7 staining was detected, a phenomenon that may 
reflect the level of confluency ofHNK cultures prior to PMA stimu-
lation (data not shown). 
To determine the specificity of this PMA-induced B7 staining, 
anti-B7 MoAbs were pre-incubated with purified recombinant B7-
Ig to block B7-specific epitopes. Such pre-incubation completely 
inhibited B7 staining on PMA-HNK (Fig 2) as well as on untreated 
HNK (data not shown). This inhibition was specific because pre-in-
cubation of the anti-B7 MoAb with a human IgG did not signifi-
cantly inhibit the MoAb binding to PMA-HNK (Fig 2). 
The next set of experiments was designed to gain insight into the 
mechanism by which PMA upregulates this molecule on HNK. To 
evaluate its dose dependency, HNK were stimulated with PMA 
concentrations ranging from 0.1 to 50 ng/ml. As shown in Fig 3, 
B7 staining rose in a linear fashion, with maximum induction at a 
concentration of25 ng/ml. In kinetic experiments, upregulation of 
B7 staining was first observed 16 h following PMA treatment and 
persisted for at least 48 II (Fig 4). Furthermore, PMA-induced up-
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Figure 3. Dose dependence of PMA-induced upregulation of B7 staining 
on HNK. Second- to fifth-passage HNK were treated with PMA at the 
indicated concentrations (16 h, 37°C, 5% CO2) and stained with MoAb 
BBl (IgM) and analyzed by FACS as described in Fig 1. HNK viability, as 
detennined by FACS using PI staining, exceeded 85% at all PMA concen-
trations tested. This graph depicts pooled data from three separate experi-
ments and is expressed as percent mean fluorescence intensity (%MFI) ± 
SO of BBl (IgM) staining, the mean fluorescence intensity of untreated 
HNK being defined as 100%. 
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Figure 4. Kinetics of PMA-induced upregulation of B7 staining on HNK. Third-passage HNK were PMA trea~ed (5 ng/ml) for the indicated time 
intervals. Thereafter, HNK were harvested, and BBl (IgM) staining was assessed by FACS, as described in Fig 1. HNK viability, as determined by PI 
staining, exceeded 90% at each time point. 
protein synthesis because it was blocked by the specific PKC inhibi-
tor GF 109203X [39] or the protein synthesis inhibitor cyclohexi-
mide, respectively (data not shown). 
Our first approach to elucidate the functional relevance ofpMA-
induced upregulation of the B7 -like molecule was based on previous 
work in which we demonstrated that PMA-HNK would induce 
proliferation of allogeneic or autologous T cells via a mechanism 
that was mediated in part by PMA-induced ICAM-l [12]. We ques-
tioned whether a B7 -transduced signal played a role in this process. 
To address this issue, the capacity of anti-B7 MoAbs to block such 
proliferation of resting (i.e., CD2S-) PBMC and T cells was deter-
mined. As described previously [12], PMA-HNK (but not untreated 
HNK) induced significant proliferative responses in allogeneic 
PBMC (Fig Sa,b) or in purified allogeneic T cells (Fig Sc,d) . The 
anti-B7 MoAb BBl reduced the capacity ofPMA-HNK to trigger 
PBMC or T-cell proliferation in a dose-dependent manner (Fig 
Sb,d) . This inhibition was specific, with control MoAb of the same 
isotype having no effect (Fig Sb,d). It is important to note that in this 
system, the anti-B7 MoAb did not abrogate PBMC or T-cell prolif-
eration completely (Fig Sb,d) . This finding suggested tbat PMA 
induced on HNK the expression of a costimulatory molecule(s) 
other than B7, which also participates in T-cell activation. Our 
previous studies made the adhesion molecule ICAM- l an attractive 
candidate because the capacity ofpMA-HNK to activate T cells was 
also blocked in part by MoAbs directed against ICAM-1 [12]. To 
determine whether PMA-induced B7-like molecules and ICAM-1 
deliver additive costimulatory signals, anti-B7 and anti-ICAM-1 
MoAbs were used alone or in combination in the above-described 
blocking experiments. Indeed, the combination of anti-B7 and 
anti - ICAM-1 had additive effects, reducing T-cell proliferation to 
nearly background levels (Fig 6). These data indicate that B7 and 
ICAM-1 expressed by PMA-HNK deliver additive accessory signals 
to T cells, ultimately leading to their activation and prolifera-
tion. 
DISCUSSION 
In the present study, we investigated the expression and function of 
the B7 Ag on KC, the major cell type within epidermis . Cultured 
KC expanded from normal human skin (HNK) display low consti-
tutive staining with anti-B7 MoAb, paralleling recent findings by 
Fleming et al and Nickoloff et al. * In our experience, such constitu-
tive B7 staining shows considerable variation, depending on the 
origin ofHNK lines and on their level of confluency at the time of 
staining. Following treatment of HNK with the phorbol ester 
PMA, a dose-dependent upregulation of B7 staining was observed. 
Such upregulation is not without precedent because treatment of 
tonsilar B cells with similar concentrations of PMA has also been 
shown to increase their B7 expression [23] . In kinetic experiments, 
upregulation ofB7 staining was first observed 16 h after PMA treat-
ment and persisted for at least 48 h, again paralleling results ob-
tained previously with B cells [18]. Furthermore, this effect was 
found to be PKC dependent and to require de novo protein synthesis 
• Fleming TE, Mirando WS, Elmets CA: Expression of the activation 
antigen BB1/B7 on cells of non-hematopoietic origin: keratinocytes from 
human epidermis (abstr). J Invest Dermatol 98:577, 1992; Nickoloff BJ, 
Mitra R, Lee K, ZeU T, Thompson C, Shimizu Y: Gamma interferon does 
not induce expression on keratinocytes of the CD28-ligand B7/BB1 
(abstr). Clin Res 40:238A, 1992. 
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Figure 5. Anti-B7 MoAb inhibits the capacity of PMA-HNK to stimulate 
proliferation of resting allogeneic PBMC or T cells. Second-passage HNK 
suspended in KGM were seeded into 96-well plates at 2 X 104 cells/dish. 
After 2 d, HNK were treated with 0 or 25 ng/ml PMA for 16 h at 37°C in 
5% CO2 , HNK were washed five times with PBS and then cocultured 
with 5 X 104 allogeneic PBMC (a and b) or purified T cells from a different 
donor (c and d) in supplemented RPM! 1640 in the continuous presence of 
MoAb BB1 (IgM) or the isotype control at the indicated concentrations. 
After 72 h, cocultures were pulsed with 1 J.lCi of TdR for an additional 
16 h; thereafter, proliferation was determined by liquid scintillation 
counting. Data are expressed as the mean cpm of triplicate cultures ± SO. 
Background proliferation of HNK, PBMC, or T cells cultured alone did not 
exceed 400 cpm. T-cell proliferation in response to 0.5 J.lg/m1 concanava-
lin A was 532 ± 64 cpm. 
on the basis of its sensitivity to the PKC inhibitor GF 109203X or 
cycloheximide, respectively. 
Does this PMA-induced staining identify bOlla fide B7 on HNK? 
We consider it unlikely that staining was nonspecific because it was 
observed using three different MoAbs directed against B7; further-
more, isotype control MoAbs, even if used at tenfold excess, did not 
stain. That the MoAbs used by us identify a molecule closely related 
to B7 is further supported by competition experiments in which 
purified recombinant B7-Ig fusion proteins totally inhibited their 
binding to PMA-HNK. On the other hand, using sensitive polymer-
ase chain reaction techniques, we have so far failed to detect signifi-
cant amounts ofB7 mRNA in untreated or in PMA-HNK. Similar 
results were obtained by Nickoloff et af (see footnote 1) using 
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Figure 6. B7 and ICAM-1 expressed by PMA-HNK deliver additive acti-
vation signals to T cells. The experiment was performed as outlined in Fig 
5, with all antibodies used at 1 J.lg/m1. 
Northern blot analysis. One explanation for these paradoxical re-
sults could be that PMA upregulates on HNK the expression of a 
surface molecule closely related but not identical to the B7 Ag. 
Although several lines of evidence suggest that BBI and B7 are 
highly related proteins encoded by the same gene [20,27] , some 
differences exist between the two. For example, MoAbs directed 
against either BB 1 or B7 have been shown to differ in their staining 
patterns of several B-cell lines and neoplasms and to immunopreci-
pitate material of different molecular weights [18] . Furthermore, 
the gene encoding for B7 has very recently been located on chro-
mosome 3 [43], whereas BBl has been previously mapped to chro-
mosome 12 [44] . On the basis of these findings, it could be possible 
that the molecule expressed by PMA-HNK is either the BB 1 glyco-
protein itself, a splicing variant of B7 or yet another distinct but 
highly related molecule. Circumstantial support for the hypothesis 
that the B7 gene may code for divergent products comes from the 
observations that B7 is not very well conserved during evolution 
(i.e. , the homology of human and murine B7, particularly of their 
cytoplasmic regions, is less than 40%) [45]. To acknowledge both 
the ambiguity in this respect and the possibility that a distinct gene 
may code for these functionally and antigenetically related mole-
cules when expressed by KC, we have chosen to cite them as B7-like 
molecules. 
Whatever the exact nature of this B7-like molecule is it was 
f?un? to. serve important costimulatory functions during T ~ce ll ac-
tivation l11duced by PMA-HNK. Specifically, anti-B7 MoAbs were 
shown to re?uce th~ cap~city ofpMA-HNK to trigger proliferation 
of allogeneic, restl11g (I.e. , CD25- ) PBMC and T cells. These 
MoAbs h~d previously been shown to inhibit the capacity of bona 
fide APC (I. e., activated B cells) to induce proliferation of allogeneic 
T cells [28,38,46]; however, our studies are the first to demonstrate 
that it can block the capacity of an "alternative" APC (i.e., KC) to 
activate T cells. Although our inhibition studies using the MoAb 
BBl strongly suggest that interactions of B7-like molecules with 
CD28 are important for this proliferative response, we have yet to 
confirm this by blocking CD28 on T cells. 
Our finding that the capacity of PMA-HNK to stimulate T-cell 
proliferation was never completely inhibited by anti-B7 MoAb sug-
gested that in addition to B7, other costimulatory molecules might 
be involved. Because our previous study had shown this prolifera-
tion to be partially ICAM-l dependent [12], we questioned whether 
interaction of PMA-induced ICAM-l with its ligand LFA-l could 
provide this additional signal. Indeed, a combination of anti-B7 and 
anti-ICAM-l MoAbs inhibited T-cell proliferation to a much 
greater extent than either reagent alone, indicating that PMA-in-
duced B7-like molecules and rCAM-l deliver additive activation 
signals to T cells. Cooperation of rCAM-l and B7 has also been 
described in other systems. For example, engagement of LFA-l 
enhances T-cell proliferation induced by anti-CD28/anti-CD2 
MoAb [47); conversely, engagement of CD28 augments LFA-l/ 
rCAM-l-mediated T-cell adhesion [30,48]. 
Our findings do not preclude, however, that in addition to 
ICAM-l and B7-like molecules, other costimulatory surface recep-
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tors contribute to T-cell proliferation induced by PMA-HNK. Do 
signals delivered by residual PMA carried over by HNK after wash-
ing add to this proliferative response? This question is important in 
light of previous findings demonstrating proliferation of purified T 
cells after effective ligation of CD28 plus PMA treatment [17,49] . It 
should be noted, however, that these studies used PMA concentra-
tions that by far exceeded those left on PMA-HNK after washing 
[12] . On the basis of our previous work, w e are confident that T-cell 
proliferation is not solely due to PMA carryover [12]; however, we 
cannot exclude the fact that trace amounts of membrane-bound 
PMA, in addition to B7-like molecules and ICAM-1, contribute to 
T-cell activation induced by PMA-HNK. 
In summary, we have demonstrated that cultured HNK activated 
ill lIitro by the phorbol ester PMA upregulate their expression of a 
molecule closely re lated to the B7 Ag. These B7 -like molecules and 
ICAM-1 , expressed simultaneously by PMA-HNK, synergize in 
inducin g proliferation of resting allogeneic T cells. On the basis of 
these findings, we hypothesize that in inflammatory dermatoses, 
"activated" EC and dermal cells also co-express "B7" and ICAM-l. 
In fact, we have observed B7 and ICAM-1 staining in lesional skin 
of patients with psoriasis, allergic contact dermatitis, and cutaneous 
T-cell lymphoma (manuscript in preparation). It is therefore not 
unreasonable to speculate that in T-cell-mediated skin diseases, 
B7-like molecules and ICAM-1 on "activated" EC and dermal cells 
cooperate to promote adhesion, activation, and cytotoxicity of 
CD28+/LFA-1+ T lymphocytes. 
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